Investigational drug · Phase 2
EC5026
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease (PD).
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "EC5026"
First trial start
2025
Nov 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EC5026", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease (PD)
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "EC5026" as an intervention, largest first.
EicOsis Human Health Inc.Industry
NCT04228302 · 40 participants · Start Dec 9, 2019 · Primary completion Jul 7, 2020
Drug: EC5026 oral capsule · For: Healthy Adults
Sites: Austin, Texas
- Novel Soluble Epoxide Hydrolase Inhibitor for Neuropathic Pain in Patients With Spinal Cord InjuryRecruiting
EicOsis Human Health Inc.Industry
NCT06438471 · 36 participants (planned) · Start May 1, 2026 · Primary completion Dec 2027
Drug: EC5026 oral tablet; Placebo oral tablet · For: Spinal Cord Injuries; Neuropathic Pain; Degenerative Disc Disease and 2 more
Sites: Augusta, Georgia
EicOsis Human Health Inc.Industry
NCT04908995 · 18 participants · Start Apr 30, 2021 · Primary completion May 12, 2021
Drug: EC5026 oral tablet · For: Healthy Adults
Sites: Austin, Texas
- Safety, Tolerability and Exploratory Efficacy of EC5026 in Parkinson's Disease (STEP Study)Recruiting
EicOsis Human Health Inc.Industry
NCT07142044 · 18 participants (planned) · Start Nov 1, 2025 · Primary completion Dec 2026
Drug: EC5026 oral tablet; Placebo · For: Parkinson's Disease (PD)
Sites: Sacramento, California
- Renal Impairment Study for Oral EC5026Recruiting
EicOsis Human Health Inc.Industry
NCT07694544 · 18 participants (planned) · Start Jul 1, 2026 · Primary completion Dec 31, 2026
Drug: EC5026 oral tablet · For: Chronic Kidney Disease
Sites: Sacramento, California
- Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Oral EC5026 in Healthy SubjectsCompleted
EicOsis Human Health Inc.Industry
NCT06089837 · 16 participants · Start Nov 28, 2023 · Primary completion Mar 13, 2024
Drug: EC5026 oral tablet; Placebo oral tablet · For: Healthy Subjects
Sites: Christchurch, New Zealand
Newest research
PubMed records naming it or its code names, newest first.
- Epoxy fatty acids reduce corneal opacity and myofibroblast activation after alkali injury.
Lu X, Morisseau C, Chen Z, et al. · Front Pharmacol 2026
- Design, synthesis, and evaluation of dual-target inhibitors of acetylcholinesterase (AChE) and soluble epoxide hydrolase (sEH) for the treatment of Alzheimer's disease.
Zhao X, Bao Y, Wan X, et al. · Eur J Med Chem 2026
- Inhibition of Soluble Epoxide Hydrolase Prevents Docetaxel-Induced Painful Peripheral Neuropathy.
Wagner KM, Yang J, Morisseau C, et al. · Int J Mol Sci 2025
- Discovery of Phenylacylpiperidine as Novel sEH Inhibitors through Scaffold Hopping of Natural Stilbene.
Ding J, Zhu MZ, Du XY, et al. · J Med Chem 2025
- Inhibitors of soluble epoxide hydrolase and cGAS/STING repair defects in amyloid-β clearance underlying vascular complications of Alzheimer's disease.
Fiala M, Hammock BD, Hwang SH, et al. · J Alzheimers Dis 2025
- Randomized, double-blind, phase 1a single-ascending dose and food effect studies assessing safety and pharmacokinetics of EC5026 in healthy volunteers.
Schmidt WK, Cortés-Puch I, McReynolds CB, et al. · Clin Transl Sci 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.